Skip to content
Clinical Trials – home

Mbal Lyulin EAD

Verified siteinfo

Bulgaria Lyulin 6, Ulitsa D-R Petir Dertliev 81, 1336 Sofia, Bulgaria

  • 2 trials recruiting
  • Psoriatic arthropathy · Rheumatoid arthritis · Hypertriglyceridaemia
  • Adult patients

About Specializations

Mbal Lyulin EAD in Sofia, Bulgaria specialises in clinical trials of conditions such as Psoriatic arthropathy, Rheumatoid arthritis, Hypertriglyceridaemia, Asthma, and other specialisations. This site conducts important research.

Main research areas of the site

Severe Hypertriglyceridemia

The medical center is at the forefront of research in Severe Hypertriglyceridemia, focusing on innovative treatments to manage and reduce elevated triglyceride levels. The center's work in this area is pivotal in developing therapies that can significantly impact patients' cardiovascular health.

  • Development of novel lipid-lowering agents
  • Impact of triglyceride reduction on cardiovascular risk
  • Long-term management strategies for hypertriglyceridemia

Through its research, the center contributes to a deeper understanding of lipid metabolism and its implications for systemic health, offering hope for improved therapeutic outcomes.

Rheumatoid Arthritis

Specializing in Rheumatoid Arthritis, the center is dedicated to advancing treatment options that enhance patient quality of life. By exploring both established and emerging therapies, the center aims to provide comprehensive care solutions for this chronic inflammatory disorder.

  • Evaluation of long-term safety and efficacy of novel treatments
  • Combination therapies for early-stage rheumatoid arthritis
  • Biosimilar development and comparative studies

The center's research efforts are instrumental in shaping future therapeutic protocols and improving patient outcomes in rheumatoid arthritis management.

Osteoporosis

In the field of Osteoporosis, the medical center is committed to pioneering research that addresses bone density loss in postmenopausal women. The center's studies focus on biosimilar development and the comparative efficacy of existing treatments.

  • Comparative efficacy of osteoporosis treatments
  • Pharmacokinetics and pharmacodynamics of bone health therapies
  • Innovations in biosimilar development

By advancing knowledge in bone health, the center plays a crucial role in developing strategies to prevent fractures and improve life quality for those affected by osteoporosis.

Progressive Multiple Sclerosis

The center's research in Progressive Multiple Sclerosis focuses on innovative imaging techniques and therapeutic interventions aimed at slowing disease progression. The center's work is vital in enhancing the understanding of disease mechanisms and treatment efficacy.

  • Quantitative MRI analysis for disease progression
  • Evaluation of novel therapeutic agents
  • Advanced imaging techniques for monitoring treatment response

Through its cutting-edge research, the center contributes to the development of more effective management strategies for progressive forms of multiple sclerosis.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Lyulin 6, Ulitsa D-R Petir Dertliev 811336 SofiaBulgaria
Recruiting now
2 trials
Conditions studied
12
Partner status
Verified site

More sites in SofiaBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

27 clinical trials

A study to evaluate the effectiveness and safety of AZD1163 in adults with moderate to severe rheumatoid arthritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AZD1163
  • Sponsor:AstraZeneca AB

Study on the Effects of Vidofludimus Calcium (IMU-838) in Patients with Progressive Multiple Sclerosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Rheumatoid arthritis

Not yet recruiting

Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Mabxience Research S.L.

Rheumatoid arthritis

Not yet recruiting

ELV001 for Active Rheumatoid Arthritis in Patients with Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years

Study of aneratrigine mesilate (iN1011-N17-02) to find the best dose for treating pain in adults with post-herpetic neuralgia

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:iN Therapeutics Co. Ltd.

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren's Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Rheumatoid arthritis

Not recruiting

Study on the Effects of IMVT-1402 for Adults with Difficult-to-Treat Rheumatoid Arthritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Previously Used Biologic Treatments

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-77242113
  • Sponsor:Janssen Cilag International

Psoriatic arthropathy

Not recruiting

Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.